A registrational trial of RM-1929
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2018
At a glance
- Drugs RM 1929 (Primary)
- Indications Head and neck cancer
- Focus Registrational; Therapeutic Use
- Sponsors Aspyrian Therapeutics
- 16 Jan 2018 This trial is expected to begin in the first quarter of 2018, according to an Aspyrian Therapeutics media release.
- 21 Jul 2017 New trial record
- 19 Jul 2017 According to an Aspyrian Therapeutics media release, the company plans to initiate this trial in the first half of 2018.